Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies - PubMed (original) (raw)

Review

. 2014 Oct;39(10):465-74.

doi: 10.1016/j.tibs.2014.08.010. Epub 2014 Sep 16.

Affiliations

• PMID: 25239057
• DOI: 10.1016/j.tibs.2014.08.010

Review

Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies

Chong Sun et al. Trends Biochem Sci. 2014 Oct.

Abstract

Mammalian cells have multiple regulatory mechanisms to deal with perturbations in cellular homeostasis, including feedback loops and crosstalk between the major signaling pathways. While these mechanisms are critically required to help cells survive under dynamic physiological circumstances, they also pose an impediment to the effective treatment of cancer. In this review, we describe what has been learned about interactions between receptor tyrosine kinase-dependent signaling pathways, and how this knowledge can be used to design rational and more effective combination therapies for cancer.

Copyright © 2014 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

Similar articles

• Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
  Brechbiel J, Miller-Moslin K, Adjei AA. Brechbiel J, et al. Cancer Treat Rev. 2014 Jul;40(6):750-9. doi: 10.1016/j.ctrv.2014.02.003. Epub 2014 Feb 24. Cancer Treat Rev. 2014. PMID: 24613036 Review.
• Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
  McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Bäsecke J, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Cocco L, Martelli AM. McCubrey JA, et al. J Cell Physiol. 2011 Nov;226(11):2762-81. doi: 10.1002/jcp.22647. J Cell Physiol. 2011. PMID: 21302297 Review.
• Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
  Polivka J Jr, Janku F. Polivka J Jr, et al. Pharmacol Ther. 2014 May;142(2):164-75. doi: 10.1016/j.pharmthera.2013.12.004. Epub 2013 Dec 9. Pharmacol Ther. 2014. PMID: 24333502 Review.
• Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
  Gadgeel SM, Wozniak A. Gadgeel SM, et al. Clin Lung Cancer. 2013 Jul;14(4):322-32. doi: 10.1016/j.cllc.2012.12.001. Epub 2013 Jan 16. Clin Lung Cancer. 2013. PMID: 23332287 Review.
• The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
  Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alvarez C, Cavazos A, Mangold GL, Patnaik A. Shimizu T, et al. Clin Cancer Res. 2012 Apr 15;18(8):2316-25. doi: 10.1158/1078-0432.CCR-11-2381. Epub 2012 Jan 19. Clin Cancer Res. 2012. PMID: 22261800

Cited by

• A price to pay for tumor regression.
  Bernards R. Bernards R. Cell Res. 2015 Jul;25(7):763-4. doi: 10.1038/cr.2015.44. Epub 2015 Apr 21. Cell Res. 2015. PMID: 25895608 Free PMC article. Review.
• Enhancing the Therapeutic Efficacy of KRASG12C Inhibitors in Lung Adenocarcinoma Cell Models by Cotargeting the MAPK Pathway or HSP90.
  Liu Y, Wu L, Lu H, Wu E, Ni J, Zhou X. Liu Y, et al. J Oncol. 2021 Nov 23;2021:2721466. doi: 10.1155/2021/2721466. eCollection 2021. J Oncol. 2021. PMID: 34858498 Free PMC article.
• Pondering the mechanism of receptor tyrosine kinase activation: The case for ligand-specific dimer microstate ensembles.
  Karl K, Hristova K. Karl K, et al. Curr Opin Struct Biol. 2021 Dec;71:193-199. doi: 10.1016/j.sbi.2021.07.003. Epub 2021 Aug 13. Curr Opin Struct Biol. 2021. PMID: 34399300 Free PMC article. Review.
• Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids.
  Gong K, Guo G, Beckley NA, Yang X, Zhang Y, Gerber DE, Minna JD, Burma S, Zhao D, Akbay EA, Habib AA. Gong K, et al. Nat Commun. 2021 Dec 1;12(1):7014. doi: 10.1038/s41467-021-27276-7. Nat Commun. 2021. PMID: 34853306 Free PMC article.
• Level of FACT defines the transcriptional landscape and aggressive phenotype of breast cancer cells.
  Fleyshman D, Prendergast L, Safina A, Paszkiewicz G, Commane M, Morgan K, Attwood K, Gurova K. Fleyshman D, et al. Oncotarget. 2017 Mar 28;8(13):20525-20542. doi: 10.18632/oncotarget.15656. Oncotarget. 2017. PMID: 28423528 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Miscellaneous

  • NCI CPTAC Assay Portal